Exercise and load modification versus corticosteroid injection versus ‘wait and see’ for persistent gluteus medius/minimus tendinopathy (the LEAP trial): a protocol for a randomised clinical trial by unknown
STUDY PROTOCOL Open Access
Exercise and load modification versus
corticosteroid injection versus ‘wait and
see’ for persistent gluteus medius/minimus
tendinopathy (the LEAP trial): a protocol for
a randomised clinical trial
Rebecca Mellor1, Alison Grimaldi2, Henry Wajswelner3, Paul Hodges4, J. Haxby Abbott5 , Kim Bennell6
and Bill Vicenzino1*
Abstract
Background: Lateral hip pain is common, particularly in females aged 40–60 years. The pain can affect sleep and
daily activities, and is frequently recalcitrant. The condition is often diagnosed as trochanteric bursitis, however
radiological and surgical studies have revealed that the most common pathology is gluteus medius/minimus
tendinopathy. Patients are usually offered three treatment options: (a) corticosteroid injection (CSI), (b) physiotherapy,
or (c) reassurance and observation. Research on Achilles and patellar tendons has shown that load modification and
exercise appears to be more effective than other treatments for managing tendinopathy, however, it is
unclear whether a CSI, or a load modification and exercise-based physiotherapy approach is more effective
in gluteal tendinopathy. This randomised controlled trial aims to compare the efficacy on pain and function
of a load modification and exercise-based programme with a CSI and a ‘wait and see’ approach for gluteal tendinopathy.
Methods: Two hundred one people with gluteal tendinopathy will be randomly allocated into one of three groups: (i)
CSI; (ii) physiotherapist-administered load modification and exercise intervention; and (iii) wait and see approach. The CSI
therapy will consist of one ultrasound (US) guided CSI around the affected tendons and advice on tendon
care. Education about load modification will be delivered in physiotherapy clinics and the exercise programme will be
both home-based and supervised. The group allocated the wait and see approach will receive basic tendon
care advice and reassurance in a single session by a trial physiotherapist. Outcomes will be evaluated at baseline, 4, 8,
12, 26 and 52 weeks using validated global rating of change, pain and physical function scales, psychological measures,
quality of life and physical activity levels. Hip abductor muscle strength will be measured at baseline and 8 weeks.
Economic evaluation will be performed to investigate the cost-effectiveness of the active interventions compared with
the wait and see approach. Analyses will be conducted on an intention-to-treat basis using logistic and linear mixed
regression models and the economic evaluation will report incremental cost-utility ratios. The trial reporting will
comply with CONSORT guidelines.
Discussion: This study will provide clinicians with directly applicable evidence of the relative efficacy of three common
approaches to the management of gluteal tendinopathy.
Trial registration: Australia New Zealand Clinical Trials Registry ACTRN12612001126808. Date Registered: 22/10/2012.
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Background
Gluteal tendinopathy or greater trochanteric pain syn-
drome is a debilitating condition, characterised by pain
situated at or around the greater trochanter of the hip,
and tenderness on palpation. Although traditionally con-
sidered to be trochanteric bursitis, more advanced im-
aging and surgical procedures in people with lateral hip
pain have revealed a primary pathology of insertional
gluteus medius or minimus tendinopathy, with bursal
distention generally a concomitant finding [1–3]. Mag-
netic Resonance Imaging (MRI) is very effective in rec-
ognizing partial and full thickness tears of the tendons
of gluteus medius and minimus, tendon calcification and
fatty muscle atrophy [2]. For the purposes of this paper
we will refer to the condition of gluteus medius tendino-
pathy, and/or gluteus minimus tendinopathy, with or
without bursal distention, as gluteal tendinopathy.
The condition is more frequent in women aged 40–60
years [4], and various studies have described its preva-
lence as ranging from 10 to 25 % of the general popula-
tion [5, 6]. A recent study of general medical practice in
the Netherlands found gluteal tendinopathy to have the
highest prevalence (4.22 per 1000 person years) and inci-
dence (3.29 per 1000 person years) of all presenting
lower limb tendinopathies [7]. The impact of gluteal ten-
dinopathy can be substantial. The pain experienced in
side lying often creates significant sleep disturbance, and
the pain commonly experienced with walking and stair
climbing usually results in reduction of physical activity
levels, which could be expected to have negative implica-
tions for general health and well-being, as well as quality
of life and employment status [8].
It is proposed that abnormal hip biomechanics may
predispose to gluteal tendinopathy [9], and although
commonly diagnosed in sedentary, overweight people
[5], it is also often seen in runners, possibly due to both
poor training habits and technique [10]. It has been
hypothesised that gluteal tendinopathy, with or without
bursitis, occurs due to compressive impingement of
these structures onto the underlying greater trochanter
by the iliotibial band (ITB) as the hip moves into adduc-
tion [11, 12]. In an upright weight bearing posture, such
as walking, weakness of the hip abductor muscles will
result in lateral pelvic tilt or ipsilateral shift in single leg
stance, and hip adduction, which will contribute to com-
pression of the tendons between the greater trochanter
and the thick fascia of the ITB.
The literature reflects an assumption that tight lateral
structures are a key issue for the development of gluteal
tendinopathy. Despite a lack of evidence of such tight-
ness, the conservative management approach commonly
suggested is stretching [13]. Compression as a primary
aetiological factor is consistent with current theories for
development of insertional tendinopathy [14, 15], and
failure to control compression in a treatment protocol
for insertional Achilles tendinopathy has been reported
to result in poor outcomes [16]. The piriformis and ilio-
tibial band stretches frequently prescribed [13] involve
sustaining the hip in forced adduction, which is a pos-
ition of high compressive loads on the gluteal tendons
[17]. We hypothesise that a specific focus on hip ab-
ductor muscle function and avoidance of compressive
loads on the tendons will provide a better approach to
achieve effective treatment outcomes.
A range of conservative management approaches are
generally recommended, including anti-inflammatory
medications, rest, ice, heat, stretching, strengthening,
ultrasound, shock-wave therapy (SWT), and local cor-
ticosteroid injection (CSI). Surgery is usually reserved
for when the condition has become refractory and con-
servative measures have failed. However, optimal man-
agement of gluteal tendinopathy remains unclear.
Reports concerning management of this condition pre-
dominantly relate to CSI and surgery. Early response to
CSI in patients with lateral hip pain is reported to be
very good, with 70–75 % of patients reporting a signifi-
cant improvement at 1 month post injection in a rando-
mised clinical trial (RCT) [13, 18]. However, at 3–4
months post injection, researchers have reported only
41–55 % positive response [13, 19]. At 12 months an
RCT showed no difference between a CSI and a group
that adopted a wait and see policy [19]. In the only clin-
ical trial (non-randomised) to date to compare CSI to
home exercise, the success rates at 1 month were 75 and
7 % respectively, but by 15 months were 48 % for CSI
and 80 % for the home exercise group [13], demonstrat-
ing only short term benefits of CSI. These studies of CSI
highlight the typical trajectory of delayed healing after a
short term improvement, which in some studies is also
coupled with substantial recurrence rates [20].
Most patients and their medical practitioners under-
standably seek a positive early response. Although
Rompe et al report patient satisfaction with a slow rate
of improvement in the early stages, a 7 % success rate
for home exercise after 1 month [13] is not convincing
evidence to recommend exercise to a patient who would
otherwise have a 75 % chance of a successful early out-
come with CSI. In contrast, outcomes from exercise and
manual therapy for a comparable tendinopathy at the
elbow (tennis elbow or lateral elbow tendinopathy, with
similar age demographic) are comparable to those from
CSI at 6 weeks (65 and 78 % success rates respectively)
and superior to adopting a wait and see approach [21].
We speculate that the low success rates at 1 month re-
ported by Rompe et al., in contrast to the high early suc-
cess rates reported by Bissett et al., is the non-specific
nature of the prescribed exercises (i.e. not targeting the
muscles specifically affected by tendinopathy, using
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stretches that increase compression), a lack of specific
load modification and management strategies related to
tendon healing, and a low level of supervision of the
home-based exercise programme.
The contemporary non-operative approach to effect-
ively managing tendinopathy involves specific exercise
for the affected muscles and load management in the
form of advice and practical strategies [15]. This ap-
proach has yet to be rigorously tested in an RCT. We
propose to test different conservative management
options for gluteal tendinopathy by comparing an ex-
ercise and load management approach supervised by
physiotherapists, CSI and the adoption of a wait and
see approach.
Our primary hypotheses are that:
HI: Both the exercise and load management programme
and the CSI will be superior to a wait and see approach
in terms of treatment success rates based on global
rating of change and reductions in pain at 8 weeks.
H2: The exercise and load management programme
will be superior to CSI in terms of treatment success
rates and reductions in pain at 52 weeks.
The secondary objectives are to: compare an exercise
and load management programme with CSI on out-
comes including pain, function, hip abductor muscle
strength, psychological measures, quality of life and
physical activity levels; evaluate the effects of the two
treatments compared to a wait and see approach on
these outcomes; determine the cost-effectiveness of the
two treatments at 52 weeks; compare the adverse events
associated with both treatments.
Methods
This is a pragmatic, assessor-blinded, RCT conducted
in medical and physiotherapy clinics in Brisbane and
Melbourne, Australia. In people with persistent gluteal
tendinopathy, it compares the effect of CSI, a physio-
therapy supervised load management, education and
exercise programme and a wait and see approach for
gluteal tendinopathy over 12 months. The trial protocol
will permit its reporting in line with the CONSORT guide-
lines [22].
Participants
Lateral hip pain, which is a symptom of gluteal tendi-
nopathy, might also present with other pathologies,
such as trochanteric bursitis, osteoarthritis, referred
lumbar spine pain, and femoral stress fracture [23].
As the load modification and exercise programme in
this trial has been designed specifically to address
gluteal tendinopathy, it is important that other differ-
ential diagnoses for lateral hip pain are excluded.
Recruitment details
We will recruit people from the community in both
Brisbane and Melbourne via advertisements in Univer-
sity News, social media and local newspapers. Initial
contact will be by phone or electronic media at which
time a preliminary screening for suitability will occur. If
the phone interview indicates potential eligibility, the
volunteer will attend the trial centre for a physical exam-
ination, which will assess against specific selection cri-
teria. Those who meet these criteria will then undergo
diagnostic imaging to confirm eligibility prior to being
included in the trial.
Selection criteria
We will include participants between the ages of 35
and 70 years who have experienced lateral hip pain
for at least 3 months, of an intensity of ≥4/10 on an
11-point numeric rating scale on most days of the
last 3 months. Table 1 outlines the selection criteria
for inclusion into the study. These criteria were based
on a previous study [13].
As clinical tests to diagnose gluteal tendinopathy ap-
pear to have limited validity [24], we have included a
small battery of clinical tests that have been considered
to be most provocative in reproducing symptoms of glu-
teal tendinopathy [23]. To be eligible, the participant
must experience pain on direct palpation of the gluteal
tendons’ insertion on the greater trochanter. They must
also test positive (reproduction of trochanteric pain) to
at least one of the following clinical tests: the Hip
FADER (passive) test, static muscle test in the FADER
position, the FABER (Patrick’s) test, passive hip adduc-
tion in side lying (ADD), a static muscle contraction in
the ADD test position, and a Single Leg Stance on the
affected leg for 30 s.
A. Hip FADER – With the patient supine, the hip is
passively flexed to 90°, adducted and externally
rotated to end of range (FADER = Flexion/Adduction/
External Rotation). The pain Numeric Rating Scale
(NRS) and area of pain is recorded. This test positions
the ITB over the greater trochanter and places the
Gluteus Medius (GMed) and Gluteus Minimus
(GMin) tendons under tension while being compressed
against the greater trochanter by the overlying fascia of
the ITB. The test is only recorded as positive if the
pain (≥2/10) is experienced over the lateral hip.
B. Hip FADER with Static muscle test (internal rotation)
at end of range (FADER-R). In the FADER position,
the participant actively resists an external rotation
force – i.e. performs static internal rotation (IR). At
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90° hip flexion all portions of GMed and GMin are
internal rotators [25]. This test requires the
participant to activate these muscles, and therefore
place further tension across their tendons, while
they are in a compressed state. Again, a positive
result refers to reproduction of pain at the lateral
hip. As clinical features of gluteal tendinopathy
include pain reproduction with elongation and
compression of the involved tendons, as well as
active contraction of these tendons, these two tests
together may have improved diagnostic accuracy.
This test is a modification of the resisted external
de-rotation test, which has been reported to have
88 % sensitivity and 97.3 % specificity [26].
C. Hip FABER – (FABER = Flexion/Abduction/External
Rotation). The lateral malleolus of the test leg is
placed above the patella of the opposite side, the
pelvis is stabilised via the opposite anterior
superior iliac spine (ASIS) and the knee is
passively lowered into abduction and external
rotation. This test places the anterior portions of
the GMed and GMin on tensile load. A positive
pain response is usually felt in the lateral hip
region. Lateral hip pain with a FABER test has
been shown to have a high sensitivity, specificity,
positive and negative predictive value (82.9, 90, 94.4
and 72 % respectively) for differentiating the diagnosis
for greater trochanteric pain syndrome from hip
osteoarthritis [27].
D. Passive Hip Adduction in Side Lying (ADD) – The
participant is placed in side-lying, with the under-
neath hip and knee flexed 80–90°, and the upper-
most leg supported by the examiner with the knee
extended, in neutral rotation, and the femur in line
with the trunk. The anterior superior iliac spines are
aligned vertically in the frontal plane. The examiner
passively moves the hip through a pure frontal plane
motion into end range hip adduction with overpres-
sure, while stablilising the pelvis with the other
hand. This test places the lateral insertions of the
gluteal tendons under compressive load, and a posi-
tive response is felt over the lateral hip. This is based
on Ober’s test, which has been reported as having a
high specificity (95 %), but a low sensitivity (41 %)
and low negative predictive value (45.2 %) [27].
E. ADD with resisted isometric abduction (ADD-R) – In
the ADD test end position, the participant is asked
to push the thigh up, against the resistance of the
examiner’s hand at the lateral knee. This test places
tensile load on the compressed tendons, with pain
elicited over the lateral hip.
F. Single Leg Stance for 30 s (SLS) – the participant
stands side-on to a wall with one finger touching
the wall at shoulder height for balance, then lifts
the foot closest to the wall, maintaining single leg
stance for up to 30 s. The participant is asked to
immediately report the development of pain by
pointing to the area of pain. If the region of the
greater trochanter is indicated, the timer is
stopped, the test ceased and recorded as positive.
This time is reported, as well as the intensity of
the pain. The single leg stance test has been
shown to have good sensitivity and specificity
(100 and 97.3 % respectively) [26] for the diagno-
sis of tendinopathy and bursitis in people with
MRI-documented gluteal tendinopathy.
Table 1 Inclusion and Exclusion Criteria
Inclusion criteria
Lateral hip pain, worst over the greater trochanter, present for a
minimum of 3 months
Age 35–70 years
Pain at an average intensity of ≥4 out of 10 on most days of the
week.
Tenderness on palpation of the greater trochanter
Reproduction of pain on at least one of five diagnostic clinical tests
(FABER test, Static muscle contraction in FABER position, FADER test,
Adduction test, Static muscle contraction in Adduction position i.e.
resisted abduction) or single leg stand
Demonstrated tendon pathology on MRI (see Table 2 for criteria)
Exclusion Criteria
Previous cortisone injection in the region of the lateral hip in the last
12 months
Physiotherapy intervention or regular appropriate Pilates in the last
3 months
Lumbar spine or lower limb surgery in the previous 6 months
Any known advanced hip joint pathology where groin pain is the
primary complaint and/or where groin pain is experienced at an
average intensity of ≥2 on most days of the week, or Kellgren-
Lawrence score of >2 (mild) on XRay.
Where range of pure hip joint flexion is <90°
Significant signs of lumbar pathology
Known advanced knee pathology or restricted range of knee
motion (must have minimum 90° flexion and full extension)




Any factors that would preclude the participant from having an MRI
(e.g. pacemaker, metal implants, pregnancy, claustrophobia)
If the participant is involved in a legal/workcover/TAC or other
injury claim
If the participant is unable to commit to an 8 week exercise
programme
with twice weekly supervised sessions
Fear of needles (trypanophobia)
If the participant is unable to write, read or comprehend English
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In addition to these tests, the physical screening will
also ensure that the participant has ≥90°hip flexion range
of movement bilaterally, knee flexion range ≥90° and full
knee extension bilaterally, and that the hip quadrant test
[28] is clear bilaterally. If groin pain on quadrant testing
is greater than 5/10 on the Pain NRS, or the difference
in pain levels between sides is greater than 2/10, the par-
ticipant is excluded. Additionally, the participant must
be able to flex the trunk forward with hands reaching at
least to the knees with ≤2/10 back pain, and have ad-
equate hip, knee and ankle mobility to be able to per-
form a squat to 60° flexion at the hips.
The participant will then be referred for MRI (if no
contraindications e.g. cardiac pacemaker, metal im-
plants etc.) and X-ray investigations at a participating
radiology clinic, as a confirmed diagnosis of gluteal
tendinopathy on MRI, based on a classification system
from a previous study [11] will also be required for
eligibility. Tendinopathy will be defined as an intra-
tendinous increase in signal intensity on T2-weighted
images (Table 2). Participants must have no contrain-
dications to MRI (e.g. cardiac pacemaker, metal im-
plants etc). An X-ray (AP and Lateral) is required to
grade osteoarthritis severity using the Kellgren-
Lawrence Scale [29]. Those with a score of >2 will be
excluded from the study. To minimize unnecessary
radiation exposure, if the patient has had previous ap-
propriate X-rays within the last 6 months, they will
not require a second lateral hip X-ray.
Concealed allocation
A computerised randomisation schedule stratified for
site (Brisbane, Melbourne) will be prepared by an in-
dependent off-site body (The Berghofer Queensland
Institute of Medical Research, Clinical Trial and Bio-
statistics Unit). To conceal randomisation, consecu-
tively numbered, sealed, opaque envelopes will be
prepared by a research assistant not involved in re-
cruitment, and kept in a locked cabinet accessible
only to the assistant. These envelopes will be opened
at each site sequentially once the participant has been
confirmed into the study by MRI, and all baseline
measurements have been completed. If allocated into
the CSI group, an appointment will be made for the
participant to receive an US-guided injection, adminis-
tered by an experienced Radiologist/Sports Physician. If
allocated into the exercise and load management group or
into the group that will adopt the wait and see approach,
an appointment will be made for the participant to attend
a trial physiotherapy clinic.
Blinding
The investigator assessing the outcome measures will be
blind to group allocation, and will not be involved in any
of the interventions. Participants will be informed in
writing and verbally that they have an equal chance of
being allocated into one of the three groups (CSI, exer-
cise and load management, wait and see). They will not
be made aware of the study hypotheses. Participants will
be requested not to divulge any details about their treat-
ment group to the investigator involved in assessing the
outcome measures, and will be reminded of this prior to
each encounter. It is not possible to blind the patients,
physiotherapists providing the treatment, the radiologist
administering the CSI, nor the physiotherapists provid-
ing the basic information to the wait and see group.
Statistical analysis will be conducted on a blinded
intention-to-treat basis.
Interventions
Corticosteroid injection: Participants allocated to this
group will attend the clinic of the experienced radiolo-
gist or sports physician who will be performing the in-
jection. Seven specialist radiologists are participating in
this trial, with a range of 15–40 years of experience. The
injection will be performed at the same radiology clinic
that the participant attended to have their MRI and
XRay investigations performed. After standard prepar-
ation procedures, the participant will be positioned on
the table with the affected side raised. A preliminary
ultrasound scan will be performed with pre procedural
images taken in a longitudinal plane. The depth of injec-
tion required will be measured and area of maximal ten-
derness marked. A linear probe which is appropriate for
Table 2 MRI Image Analysis – Classification of Pathology for
definition of gluteal tendinopathy
T2 Hyperintensity around Greater Trochanter (representing oedema/fluid)
Size (1) Tiny (thin slit of fluid)
(2) Small (localized, mild distension)
(3) Medium (localized, moderate distension)
(4) Large (localized, marked distension)
Shape (1) Feathery
(2) Crescentic




(4) Superficial to fascia lata
Partial thickness tear Tendon irregular, thinned or focally
discontinuous
Full thickness tear Discontinuity and/or retraction of the
torn tendon from greater trochanter
*Intratendinous high T2 signal considered as tendinopathy with a
thickened tendon without any irregularity, tendon thinning, or focal
tendon discontinuity
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the participant body habitus (i.e. 12 MHz) will be cleaned
using sterile wipes, and the appropriate syringe and needle
selected. A further preliminary scan will be performed,
and the radiologist washes their hands and gloves up. The
steroid (Celestone 1 ml or Kenacort A40 1 ml (depending
on availability)) and local anaesthetic (Bupivacaine 2 ml or
Marcaine 1 ml) will be drawn up using sterile techniques
and the participant’s skin and ultrasound probe will be
cleansed with chlorhexidine and the area draped. The
radiologist will place the needle through the superficial
structures until it reaches the bursa following which the
steroid and local anaesthetic mixture will be injected
widely in different directions through the bursa. On com-
pletion of the procedure, a dressing will be applied to the
puncture site. A post procedural check will be performed,
and a further explanation of what to expect and basic ad-
vice on tendon care will be given to the participant. A
weekly diary will be completed, recording levels of pain
and function and any adverse effects.
Exercise, education and load management programme:
Participants allocated to this group will be prescribed a
home exercise programme to be performed daily, which
will be limited to four to six exercises (to optimise ad-
herence), and should take no longer than 15–20 min to
complete. Participants will also receive more specific
and detailed advice and education on tendon care. This
information will be delivered in hard copy handouts,
verbal explanation and DVD. They will attend the
physiotherapy clinic for individual supervised exercise
sessions, and be treated by an experienced and regis-
tered musculoskeletal physiotherapist. Treating practi-
tioners will have attended a training session outlining
the study objectives and requirements, demonstrating
the exercise protocol and progressions, as well as the de-
tailed education material, and will be expected to be
proficient in the intervention. They will also be provided
with a detailed study manual for reference. The physio-
therapy sessions will be once a week for the first 2 weeks,
then twice a week for the next 6 weeks. The first session
will be 1 h long, in order to perform detailed education
and demonstration of the exercises. Successive sessions
will be 30 min in duration, and include a brief interview
and physical assessment to gauge the response to the ex-
ercise and load management program, modify or pro-
gress the home exercises, and supervise a twice weekly
heavier loading exercise programme.
The exercises will include functional retraining, and tar-
geted strengthening for the hip and thigh muscles, with a
particular focus on the hip abductor muscles, and dy-
namic control of adduction during function. Exercise diffi-
culty will be gradually increased as tolerated by the
participant, in order to optimise improvements in muscle
strength and function without significant aggravation of
the participant’s pain. Difficulty level will be monitored
with the Borg Scale [30] where warm up will be performed
at a light level (Borg 11–12), functional retraining at a
somewhat hard to hard level (Borg 13–15), and the slow
heavy targeted strengthening moving from somewhat
hard towards the hard to very hard level (14–17), de-
pending on the participants response to loading. No
change in pain over the greater trochanter will be ac-
ceptable during functional retraining, as this may in-
dicate inadequate alignment control, and excessive
compressive tendon loading. As the heavy slow
strengthening exercises avoid tendon compression
completely, a maximum of NRS 5/10 pain will be tol-
erated as long as this eases afterwards and does not
result in increased pain levels that night or the next
morning. Participants’ responses to the exercises will
be closely monitored, and loading levels adjusted as
required to prevent any increases in pain from week
to week. Table 3 outlines the clinic and home based
exercise protocols, and Figs. 1 and 2 show some ex-
amples of the prescribed exercises.
Adherence to the exercise programme will be moni-
tored by the physiotherapists and with the partici-
pants also completing a daily diary, outlining the
exercises completed (number of sets and repetitions),
any adverse responses and action taken. If any ad-
verse event occurs during the treatment period, the
participants will also be encouraged to report directly
to their physiotherapist (e.g. worsening of pain, new
symptoms or any injury). Any reports of adverse
events will be recorded in the treatment notes and
diary. The diary will be collected from the participant
at the 8 week follow up assessment.
Wait and see: Participants allocated to adopt a wait
and see approach will attend one session with a trial
physiotherapist, where they will receive reassurance that
the condition is likely to resolve over time, as well as ad-
vice regarding general tendon care and self-management.
They will also receive a standard information pamphlet
about the condition and basic self-management. The ther-
apists will take time to answer any questions about adopt-
ing a wait and see approach to ensure the participant is
confident that this is an appropriate and sensible approach
to adopt. Participants in this group will complete a weekly
diary, outlining any problems that may have been encoun-
tered related to the study.
Outcome measures
A battery of primary and secondary outcome measures
will be recorded. They are summarized in Table 4.
Primary outcome measures
There are two primary outcome measures: (1) Global
Rating of Change Score, and (2) Average Pain over the
previous week.
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Table 3 Exercise Dosage and Progressions
Stage Exercise Effort Speed Reps Sets Freq
Week 1- Familiarisation Low load activations Light Slow onset 10 1–2 BD
Static Abduction: Hold 5–10 s
In supine lying Light Slow onset 3–5 1 BD
In standing Hold 5–15 s
Pelvic Control during Functional Loading: daily
Bridging Light Moderate 10 1 daily
Double Leg Bridging
Functional Strengthening: Light- SWH Slow 10 1
Double leg squats
Abductor Loading via Frontal Plane
Movement:
Light Moderate 10 each 1 daily
Sidestepping
Week 2 – Early Loading &
Movement Optimisation
Low load activations Maintain as per week 1
Static Abduction:
Pelvic Control during Functional Loading:
Bridging:
Double leg bridging Light Slow 10 1 daily
Single leg biased ex: SWH Slow 5 1
Offset bridging
Functional Strengthening:
Double leg squats Light Slow 10 1 daily
Single leg biased ex: SWH Slow 5 1
Offset squat
Abductor Loading via Frontal Plane
Movement:
Light Moderate 15 each 1 daily
Sidestepping
Week 3–8 – Graduated Loading Low load activations Maintain as per week 1
Static Abduction:
Pelvic Control during Functional Loading:
Bridging: Light Slow 5 1 daily
Double leg bridging
Single leg biased ex SWH – Hard 5–10 2 daily
Functional Strengthening:
Double leg squats Light Slow 5 1
Single leg biased ex SWH - Hard 5–10 2
Abductor Loading via Frontal Plane
Movement:
daily
Sidestepping Light Moderate 10 each 1
Band Sideslides SWH- Hard 5–10 each 1–2
Week 3–8 – Graduated Loading;
Sliding platform with spring resistance
All supervised by Physiotherapist in Clinic
Warm up Abductor Loading via Frontal Plane
Movement:
Bilateral Abduction: Twice weekly
In upright Light Moderate 5 each way 1
In minisquat Light Moderate 5 each way 1
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1. The Global Rating of Change Scale (GROC) is an
11-point scale in which the participant is asked to
rate their perceived overall change in condition of
their hip from the time that they began the study
until the present, as Worse, No Change, or Better.
If they indicate worse, the patient will then be
asked how much worse on a five-point scale from
Very Much Worse to Slightly Worse, and if they
are better, they will be asked how much better on a
five-point scale from Slightly Better to Very Much
Better [31] (Fig. 3). Measuring patient perceived
change using scales such as the GROC scale has
previously been shown to be clinically relevant and
a stable concept for interpreting meaningful im-
provements from an individual perspective [32].
2. The average pain over the previous week is measured
on an 11-point Pain Numeric Rating Scale (NRS), with
terminal descriptors of 0 = ‘no pain’ and 10 = ‘worst
pain possible’. The minimum important difference
(MID) for the NRS has been found to be -1.5 points
for musculoskeletal disorders [33].
Secondary outcome measures
To ensure we have sufficient information regarding treat-
ment responses there are a battery of secondary outcome
measures: (1) Hip abductor muscle strength, (2) The
VISA-G questionnaire, (3) the Patient Specific Functional
Scale (PSFS), (4) the Pain Self-Efficacy Questionnaire, (5)
The Pain Catastrophising Scale, (6) the Patient Health
Questionnaire 9 (PHQ9),(7) the Active Australia survey,
(8) EuroQoL (EQ-5D™) and (9) modified Osteoarthritis
Costs and Consequences Questionnaire (OCC-Q).
1. Hip abductor muscle strength will be measured with
the participant in the supine position, with the
tested leg extended and the hip at 10° abduction and
0° flexion, and the opposite leg flexed at the hip and
knee. The pelvis will be stabilized with a seatbelt and
towel, strapped to the plinth, and the participant will
hold the side of the plinth with both hands. The
centre of the dynamometer (Nicholas, Lafayett,
IN47903 USA) will be positioned above the lateral
malleolus of the fibula. Although such devices have
Table 3 Exercise Dosage and Progressions (Continued)




In upright SWH-VH Slow 5–10 each way 1
In minisquat SWH-VH Slow 5–10 each way 1
Pelvic Control during Functional
Loading:
Light - SWH Moderate 5–10 1–2 Twice weekly
Scooter
Repetitions (Reps); Frequency (Freq); Effort based on Borg Scale (Borg, [30]); Somewhat Hard (SWH); Very Hard (VH); Speed: Slow = 3 s each movement phase – up/
down/in/out; Moderate = 2 s each movement phase; Bi-daily (BD)
Fig. 1 Offset bridging exercise
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been shown to have good to excellent reliability in
different populations [34], a strap will be placed
around the dynamometer and the plinth to stabilize
the dynamometer and provide resistance to the
abducting force, to eliminate the potential effect of
examiner strength [35] (Fig. 4). The distance
between the centre of the dynamometer and the
most lateral aspect of the greater trochanter will be
measured to calculate lever arm length. The supine
position was adopted rather than side lying, as many
people suffering from gluteal tendinopathy are
unable to lie on the affected side due to pain. It has
been found that the supine position also produces
less measurement variation than the side lying
position when testing hip abduction strength with
a dynamometer [36]. Each participant will have
one practice trial, followed by three experimental
trials of hip abduction strength. To avoid pain
aggravation, the participant will be asked to ramp
up their force gradually, and then maintain a
maximal contraction for 5 s. Peak force (Newtons)
will be noted for each contraction, and the maximal
value achieved over the three repetitions will be
recorded. The distance between the greater
trochanter and the mid-point of the dynamometer
placement (proximal to the lateral malleolus) is
then measured (m). Torque (Nm) is then calcu-
lated by the equation T = F (N) × D (m), and
then standardized to body weight (Nm/kg). Standard
verbal encouragement will be provided, with a consist-
ent volume and level of enthusiasm. Fifteen seconds
rest will be allowed between each contraction. A pain
score will also be recorded for each repetition. This
strength test has excellent test-retest reliability in our
laboratory (ICC (95 % CI): 0.90 (0.83–0.95)).
2. The VISA-G questionnaire is a self-reported,
patient-specific tool for evaluating the severity of
Fig. 2 Spring resisted abduction on a sliding platform
Table 4 Primary and Secondary Outcome measures
Primary outcomes Measurement Baseline 4 weeks 8 weeks 12 weeks 26 weeks 52 weeks
Average Pain over the last week 11-point Pain Numeric Rating Scale (NRS),
with terminal descriptors of 0 = ‘no pain’
and 10 = ‘worst pain possible’
√ √ √ √ √ √
Perceived overall change in condition
of Hip
Global Rating of Change Scale √ √ √ √ √
Secondary Outcomes Measurement
Global Impact of pain Lateral Hip Pain Questionnaire √ √ √ √ √ √
Function Patient Specific Functional Scale √ √ √ √ √ √
Quality of life EuroQoL √ √ √ √ √ √
Muscle strength Static painfree abductor muscle strength √ √
Muscle Function Active Lag Abductor Muscles √ √
Pain Catastrophising Pain Catastophising Scale √ √ √ √ √ √
Depression PHQ-9 √ √ √ √ √ √
Pain and Function VISA-G √ √ √ √ √ √
Pain Self-Efficacy Pain Self-Efficacy Questionnaire √ √ √ √ √ √
Physical Activity Levels Active Australia Survey √ √ √ √ √ √
Economic Costs OCC-Q √ √ √
EuroQoL European quality of life questionnaire, PHQ-9 patient health questionnaire-9; OCC-Q osteoarthritis costs and consequences questionnaires
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disability in people with gluteal tendinopathy, and is
modelled on other VISA questionnaires previously
developed for Achilles and patellar tendinopathies,
that have been shown to be valid and reliable tools
for establishing severity of tendinopathy [37, 38].
This questionnaire consists of 8 items, addressing
pain and function at the present time. Scores range
from 0 to 100, with higher scores indicating less pain
and better function. The VISA-G demonstrates good
reliability and validity [39], providing an objective
method for measuring changes in the severity of
disability of people with gluteal tendinopathy.
3. The Patient Specific Functional Scale (PSFS) is a
self-reported, patient-specific measure, designed to
assess functional change in patients presenting with
musculoskeletal disorders, and has been shown to be
reliable, valid, and responsive to change in a number
of musculoskeletal populations [40–42]. Patients are
asked to identify three important activities they are
unable to perform or are having difficulty with be-
cause of their problem. They are then asked to rate
the current level of difficulty associated with each
activity on an 11-point scale (where 0 is ‘unable to
perform the activity’, and 10 is ‘able to perform at
the same level as before the injury or problem’). Fol-
lowing intervention, the patients are then asked to
rate the activities previously identified [43]. A total
score is obtained by the sum of the activity scores,
divided by the number of activities. Lower scores in-
dicate greater functional difficulty. The MID has
been found to be between 2.3 and 2.7 PSFS points in
patients with musculoskeletal disorders of the lower
extremity [33].
4. The Pain Self-Efficacy Questionnaire (PSEQ) [44]
is a ten-item questionnaire used to assess the
confidence that people with chronic pain have in
Fig. 3 Primary Outcome Measure 1: Global Rating of Change Scale, modified from Kamper et al [31]
Fig. 4 Measurement of maximum static abductor muscle strength
Mellor et al. BMC Musculoskeletal Disorders  (2016) 17:196 Page 10 of 17
performing activities while in pain. It covers a
range of functions, including household chores,
socialising, work, as well as coping with pain
without medication. It takes 2 min to complete,
has a high completion rate, can be used in assess-
ment, treatment planning, and outcome evaluation
[44], and has been shown to be a reliable and
valid measure [45]. Participants are requested to
rate how confidently they can presently perform
the activities described on a seven-point Likert scale,
where 0 = not at all confident and 6 = completely
confident. The total score ranges from 0 to 60, where
higher scores reflect stronger self-efficacy beliefs.
5. The Pain Catastrophising Scale is a 13-item self-
report scale to measure pain catastrophising, and
has been shown to be valid and reliable [46]. Par-
ticipants are asked to reflect on past painful expe-
riences and to indicate the degree to which they
experienced each of 13 thoughts or feelings when
experiencing pain, on 5-point scales with the end
points (0) not at all and (4) all the time. The Pain
Catastrophising Scale produces a total score, and
three subscale scores assessing rumination, magni-
fication and helplessness. The total score ranges
from 0 to 52, with higher scores indicating higher
levels of pain catastrophization. Pain catastrophis-
ing is said to relate to various levels of pain inten-
sity reporting, physical disability and psychological
disability in clinical and nonclinical populations.
6. The Patient Health Questionnaire 9 (PHQ-9) is a
brief self-report tool for screening, diagnosing,
monitoring and measuring the severity of depres-
sion. The nine item questionnaire determines the
frequency of depressive symptoms over the past
2 weeks, where PHQ-9 scores of 5, 10, 15 and 20
represent mild, moderate, moderately severe and
severe depression. In addition to making criteria-
based diagnoses of depressive disorders, the PHQ-9
has been shown to be a valid and reliable measure of
depression severity, and its brevity makes it a useful
clinical and research tool [47]
7. The Active Australia Survey measures participation
in leisure-time physical activity. The core questions
apply to 1 week preceding completion of the survey,
and consist of a short and reliable set of eight ques-
tions that can be easily implemented via telephone
interviewing techniques or in face-to-face interviews.
The Active Australia Survey has good reliability and
validity and has been used in national surveys [48].
A number of different measures of participation in
physical activity during the previous week can be
obtained, including how many sessions of physical
activity, total time and average time spent in each
activity and ultimately the proportion of people
who were doing sufficient activity to gain health
benefits, or those who were sedentary.
8. The EuroQoL (EQ-5D™) is a standardised instrument
for use as a measure of health-related quality of life. It
is applicable to a wide range of health conditions and
treatments, and provides a simple descriptive profile,
where the participant indicates in tick boxes which
statements about mobility, personal care, usual activ-
ities, pain and anxiety/depression best describe their
health status, as well as a single index value for health
status. The participant is asked to grade their current
level of function in each dimension into one of 3° of
disability (severe, moderate or none), and each health
state is ranked and transformed into a single score,
called the utility. This utility score is an expression
of the Quality Adjusted Life Years (QALY), and is
commonly used to make evidence-based decisions
in analyses of cost-effectiveness [49]. It is designed
for self-completion by respondents and is cognitively
simple, taking only a few minutes to complete.
9. Economic costs data will be obtained from a
modified version of the Osteoarthritis Costs and
Consequences Questionnaire (OCC-Q). It is a
self-administered questionnaire, which gives a
broad representation of health care costs, and has
been shown to be a feasible and valid method of
capturing health care use and costs for patients
with hip or knee pain compared with accessing
administrative databases [50].
Other measures
Several other measures will be included to provide add-
itional information about participants, such as demo-
graphic information collected at phone interview and
the initial physical screen. Participants in the CSI and
wait and see groups will keep a weekly diary throughout
the initial 8 weeks to record any adverse events and any
co-interventions, including pain related medication use.
This same information is captured via the daily diary in
the physiotherapy group.
In addition to these measures the opportunity presents
to test two novel condition-specific measures: (1) the
Lateral Hip Pain Questionnaire (LHPQ) and (2) the hip
abduction lag.
1. The LHPQ has been designed as a self-reported
measure of pain and function with focus on issues
specific to lateral hip pain sufferers. It has two pri-
mary subscales – one for Activities of Daily Living
(ADL), and one for Sport. The ADL subscale en-
compasses questions related to pain (frequency,
overall intensity, intensity for specific tasks, time to
pain onset, and pain duration after sustained sitting),
impact on function (overall and specific activities),
Mellor et al. BMC Musculoskeletal Disorders  (2016) 17:196 Page 11 of 17
and pain beliefs (fear of physical activity, and per-
manent impairment). The participant is asked to
consider these aspects over the past week, and the
total score ranges from 0 to 100, with higher scores
indicating less pain and better function. The Sports
subscale requires self-rating of pain (pain intensity
while participating in sport, pain behaviour, time to
pain onset) and impact on sporting participation. It
is not completed if the participant does not compete
in sport. Again, the time frame is considered over
the past week, and the total score ranges from 0 to
100. The LHPQ is in a development phase, and will
be tested alongside this main trial, and validated
against information collected from other concurrent
outcome measures (VISA-G) (Additional file 1).
2. Active lag of hip abduction (Active -Passive
discrepancy) will be measured with the participant
in the side-lying position, with the lower leg against
the table in approximately 45° of hip flexion and 90°
of knee flexion. The upper leg will be supported on
pillows in a neutral position in the sagittal plane,
with 10° abduction in the frontal plane to avoid
compressive loading of the ITB over the greater
trochanter. Rotation of the pelvis will be avoided,
and a rolled towel will be placed under the waist
angle to achieve a neutral lumbo-pelvic position.
The assessor will stand behind the patient to ensure
the pelvis is maintained in the starting position, and
also stabilise the pelvis with a hand over the lateral
iliac crest. A plurimeter (Australasian Medical &
Therapeutic Instruments) will be placed on the distal
femur, 5 cm proximal to the lateral joint line. The
participant will be requested to actively abduct the
hip to the maximal position that they are comfort-
ably capable of, and this position will be recorded.
The assessor will then passively abduct the hip to its
end of range, stabilising the pelvis and supporting
the lower leg, and this position will be recorded. A
trial of this active and passive abduction movement
will be performed first in order to ensure correct
technique (hip in neutral flexion/extension and
rotation), then this will be repeated three times.
The difference between passive and active range
of hip abduction is recorded as the Active Lag for
each repetition, and the average of the three trials
will be recorded for analysis.
Procedure
The flow of participants through the study is outlined in
Fig. 5. Following baseline testing and imaging, eligible
participants will be randomly allocated into one of three
groups: (1) CSI, (2) exercise, education and load man-
agement programme, or (3) wait and see. Participants
will complete the questionnaire outcome measures at
baseline and 4, 8, 12, 26 and 52 weeks after com-
mencement of the study, and physical outcome mea-
sures (abductor muscle strength and lag) will be
reassessed at 8 weeks. Regular contact will be main-
tained with participants via phone calls and emails to
ensure completion and return of questionnaires at all
time points. Participants will be asked to refrain from
seeking other treatments during the study period, but
analgesia and anti-inflammatory drugs will be permit-
ted. All medication use and co-interventions will be
recorded.
Not per protocol treatments
All participants will be informed of the importance of
following allocated treatments, but encouraged to record
in their diary any deviations from protocol. Not per
protocol treatments are for example, medications, other
injections, other physiotherapy or treatment not speci-
fied by the allocation.
Adverse events
Participants, physiotherapists and medical practitioners
performing the treatments will report adverse effects to
the research assistant who with the chief investigator
will then ensure that if required the appropriate treat-
ment for that adverse effect is undertaken and that the
event is reported to the ethics committee. The partici-
pant will be monitored over the course of resolution.
Data management
The responses to the GROC scale will be dichotomized,
where “Success” will be defined as “Moderately better”
to “Very Much Better”. The proportion of improved par-
ticipants from each group will determine success of the
intervention.
Sample size
The treatment effect will be evaluated by comparing suc-
cess rates on the primary outcome measure of the
GROC score between groups. For the global rating of
change score, sample size is based on the ability to de-
tect a clinically relevant difference of 30 % in success
rate between the two treatment groups and the control
at eight weeks from baseline using the Dunnett’s test
procedure. This sample size accounted for a 15 % loss to
follow-up, a type I error rate of 0.05, any-pair power of
0.95 and all-pair power of 0.80. Assuming a success rate
of 40 % for the control (the wait and see group), 70 %
for the physiotherapy group and 70 % for the CSI group,
the target sample size was calculated at 67 patients per
group for a total sample size of 201 which is based on
2000 Monte Carlo sampling with the equivalence margin
of 20 %. This sample size was chosen because a sample
size of 61 per group was required for a point estimate of
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effect of two points on the 11 point pain numerical rat-
ing scale (the other primary outcome). The Clinical Trial
and Biostatics Unit of the Berghofer Queensland Insti-
tute of Medical Research was responsible for calculating
sample size.
Statistical analysis
Statistical analyses will be conducted on a blinded
intention-to-treat basis, with all participants who were
initially randomised into the study included where data
are available for each measurement time point.
The outcomes measured at baseline, 4, 8, 12, 26
and 52 weeks will be analysed using linear mixed and
logistic regression models that will include their re-
spective outcome measure scores as a covariate, par-
ticipants as a random effect and treatment conditions
as fixed factors. Variables such as age, sex, body mass
index (BMI) and site will be included as covariates in
the analysis. Regression diagnostics will be used to
check for normality of the measures and homogeneity
of variance where appropriate. Treatment mean con-
trasts will be defined a-priori: CSI versus load modifi-
cation and exercise intervention, CSI versus wait and
see approach, and load modification and exercise
intervention versus wait and see approach. Alpha will
be set at 0.05. Numbers needed to treat index will
also be calculated.
The cost and utility data will be analysed in a manner
consistent with the clinical outcome data. The resource
use data captured by the OCC-Q will be valued using
unit costs derived from local and national sources. If the
cost data violate the assumptions of parametric statistics,
Fig. 5 Flow of participants through RCT
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non-parametric methods of analysing group means will
be used. Non-parametric bootstrapping will be used for
calculating means and confidence intervals. Estimates of
the costs and effects of each treatment group in relation
to the comparator and to each other will be presented,
with sampling uncertainty. The incremental differences
between these groups will be reported as incremental
cost-effectiveness ratios (ICER), reported from both the
societal perspective (primary) and the health system per-
spective (secondary), and will be presented in cost-utility
scatter planes. Confidence intervals will be calculated for
the ICERs. Sensitivity analyses will also be conducted to
test the robustness of the models. Cost-effectiveness
acceptability curves (CEACs) will also be calculated to
determine the likelihood that the treatments can be con-
sidered cost-effective at the commonly accepted, policy-
relevant willingness-to-pay (WTP) thresholds of one,
two, and three times GDP per capita.
Discussion
Despite its prevalence in the community and the associ-
ated disability that ensues, optimal management of glu-
teal tendinopathy has not been established. We propose
that to effectively address the deficit in evidence for opti-
mal management of gluteal tendinopathy, an RCT that
compares commonly prescribed treatments, such as CSI,
adopting a wait and see approach, and physiotherapy is
required. In addition to this, current evidence suggests
that management of tendinopathy needs to be targeted
to the tendon and in that regard: (a) the diagnosis
should involve a combination of clinical examination
and MRI confirmation of tendon involvement, (b) an in-
jection should be guided by imaging so as to be specific
[51] and (c) any exercise be undertaken as part of a load
management approach, which is now being recom-
mended as the frontline treatment for managing tendi-
nopathy [15].
Identification of the appropriate patient population in
an RCT is critical both for the targeted applications of
treatment and applicability of the study results to pa-
tients in the clinic. A patient presenting with lateral hip
pain might have a number of musculoskeletal conditions
acting as the potential source of pain around the lateral
hip area. In addition to hip joint pathology, such as
osteoarthritis, inflammatory arthritis, avascular necrosis
or infection, other extra-articular causes of lateral hip
pain reported in the literature include femoral neck
stress fractures, spinal referred pain, nerve entrapment
and tumours [3]. A strength of our proposed RCT is that
we will use a combination of both clinical tests and MRI
diagnosis that implicate gluteal tendinopathy as our key
selection criteria. This is crucial to the outcomes of the
trial, as the injection and the exercise and load manage-
ment programme are specifically designed to manage
and treat the condition of gluteal tendinopathy, rather
than other hip conditions.
Corticosteroid injections are widely used in the man-
agement of many tendinopathies [20] including gluteal
tendinopathy. One of the reasons they are widely used is
likely due to the remarkable improvement in pain re-
ported by patients in the first 4–8 weeks. The review by
Coombes et al identified that only for lateral epicondy-
lalgia of the elbow has there been evidence from several
high quality RCTs that show that this early good effect is
followed by delayed recovery when compared to adop-
tion of a wait and see approach. Also, substantially
higher recurrence rates were seen with CSI compared to
when a wait and see approach or manual therapy and
exercise was adopted. Notwithstanding these poor long-
term outcomes, the likelihood of serious adverse effects
of a CSI were rare and relatively minor in nature [20],
and usually only include increased or radiating pain,
local skin irritation or swelling, local soft tissue atrophy,
infection or depigmentation [52]. It is likely that the
combination of few adverse effects and a high propor-
tion of favourable responses in the short term is one
of the reasons for the continued use of these injec-
tions. We will minimise adverse events in our study
through the use of well-trained medical practitioners
who will utilise image guidance, as well as providing
post-injection advice to manage load and its re-
introduction in a graduated manner over the ensuing
6–8 weeks. That is, the patient will be warned that
they could experience a recurrence if they overload
the tendon too quickly after the injection and that
there would be a temptation to do so as their pain
would be much better during this period.
Participants allocated into the wait and see approach
group will attend a single session with a trial physiother-
apist, who will describe the condition and its develop-
ment, provide reassurance that the condition will
spontaneously improve over time, and advise a sensible
approach to continued safe, non-painful activity. A num-
ber of RCTs comparing treatment approaches for lateral
elbow tendinopathy have shown that by 12 months there
is good resolution of the condition and no significant
differences in outcome measures (e.g. pain, patient satis-
faction, global improvement) between a wait and see
group, CSI and physiotherapy [21, 53]. An RCT that
compared CSI and usual care (analgesics as needed) in a
population of people with greater trochanteric pain syn-
drome also found no significant differences in recovery
(61 and 60 % totally or strongly recovered) and pain at
rest or with activity between the two groups at 12 months
[19]. Thus, despite a slower resolution, in the long term
the wait and see approach is often superior to a CSI as
outcomes are better and there is a lower recurrence rate
(as observed in lateral elbow tendinopathy) [21].
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Exercise and load management is proposed to be the
cornerstone of an effective non-operative approach to
tendinopathy [15]. We have chosen to investigate an
exercise and load management approach that focuses
specifically on hip abductor muscle function and avoid-
ance of compressive loads on the gluteal tendons. The
exercise programme avoids commonly adopted/pre-
scribed hip muscle stretching techniques, because they
are likely to place high compressive load on the ten-
dons. It also limits hip adduction in the exercises that
are used to facilitate and condition the gluteal muscles.
The gluteal exercises are commenced at low loads that
are gradually progressed over the course of treatment.
The education element of this program reinforces the
attention required to avoid or minimise compressive
loading of the tendons. It does this by showing the
patient through multimedia and personal instruction
ways in which to minimize compressive loading of the
tendons during everyday activities. We propose that
this will provide the best circumstances under which to
test conservative management against CSI and the
adoption of a wait and see approach, both in the short
and long term for both recovery and recurrence rates.
In order to optimise the rigor of the RCT and to min-
imise bias, a number of methodological factors have
been incorporated into the design of the study. The
study participants will be randomly allocated into the
intervention groups via concealed allocation, as inad-
equately concealed allocation has been associated with
bias in RCTs [54]. Due to the nature of the interven-
tions, it is not possible to blind the participants or the
treating therapists to the allocated groups.
In further attempts to reduce bias, data will be ana-
lysed on an intention-to-treat basis, which preserves the
randomisation process and also imitates the real life
situation where the possibility exists that not all partici-
pants receive their prescribed treatment. Additionally,
the statistical analysis will be conducted blind to treat-
ment group allocation.
The RCT will utilise outcome measures that have
established reliability and validity, as recommended by
the CONSORT group [55]. In addition to improving
measurement quality and outcomes, it also enables
direct comparisons with other studies that investigate
conservative management of gluteal tendinopathy and
possible meta-analyses. The outcome measures are
easily administered in a clinical setting, which will en-
hance the relevance and application of study findings
to clinicians.
Conclusion
An evidence-based, effective, appropriate conservative
management strategy for gluteal tendinopathy that pro-
vides both short- and long-term benefits in terms of
reduction of pain and improvement in function is needed.
This RCT will implement high-quality methodologies in
accordance with CONSORT guidelines. It is anticipated
that findings from this study will contribute to the body of
evidence-based practice available to clinicians in order to
provide effective management of gluteal tendinopathy.
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The trial adheres to the principles of the Declaration
of Helsinki with ethical approval obtained from the
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of the University of Melbourne (Ethics ID 1238598). All




This is a study protocol, and this trial is presently in pro-
gress. Thus, no data are currently available.
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Additional file 1: Lateral Hip Pain Questionnaire. (PDF 336 kb)
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